Pathophysiology of Abdominal aortic aneurysm relevant to improvements in patients' management

Current Opinion in Cardiology

Volumn 24, Issue 6, 2009, Pages 532-538

  Golledge, Jonathan ^a   Norman, Paul E ^b  

^a JAMES COOK UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Abdominal aortic aneurysm; Biomarker; Functional imaging; Medication

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CROMOGLYCATE DISODIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE; ROXITHROMYCIN; TRANILAST;

ABDOMINAL AORTA ANEURYSM; AORTA THROMBOSIS; BLOOD EXAMINATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; ENZYME INHIBITION; GENETIC MARKER; HUMAN; INFLAMMATORY CELL; INTERVENTION STUDY; MAST CELL; MONITORING; NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVIEW;

ANEURYSM, RUPTURED; AORTIC ANEURYSM, ABDOMINAL; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; TREATMENT OUTCOME;

EID: 74249085173     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328330c2d3     Document Type: Review

References (78)

1. Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 2006; 26:2605-2613. (Pubitemid 44777272)
2. Population Health Division. The health of the people of New South Wales - Report of the Chief Health Officer. Sydney: NSW Department of Health. Available at: http://www.health.nsw.gov.au/public-health/chorep/cvd/cvd-aa.htm. Accessed 14/12/07.
3. Miniño A, Heron M, Smith B, Kochanek K. Deaths: final data for1999. National vital statistics reports. Hyattsville, MD: National Center for Health Statistics. Viewed at http://www.cdc.gov/nchs/data/statab/lcwk9.pdf on 15/9/07.
4. Timaran CH, Veith FJ, Rosero EB, et al. Endovascular aortic aneurysm repair in patients with the highest risk and in-hospital mortality in the United States. Arch Surg 2007; 142:520-524.
5. Golledge J, Parr A, Boult M, et al. The outcome of endovascular repair of small abdominal aortic aneurysms. Ann Surg 2007; 245:326-333.
6. EVAR trial participants. Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. Lancet 2005; 365:2179-2186.
7. Jones WB, Taylor SM, Kalbaugh CA, et al. Lost to follow-up: a potential underappreciated limitation of endovascular aneurysm repair. J Vasc Surg 2007; 46:434-440.
8. Epstein DM, Sculpher MJ, Manca A, et al. Modelling the long-term costeffectiveness of endovascular or open repair for abdominal aortic aneurysm. Br J Surg 2008; 95:183-190. Based on data from the EVAR 1 trial endovascular AAA repair was estimated to cost £3800 more per case than open repair.
9. Fleming C, Whitlock EP, Bell TL, Lederle FA. Screening for abdominal aortic aneurysm: a best-evidence systematic review for the US Preventive Services Task Force. Ann Int Med 2005; 142:203-211.
10. Golledge J, Tsao PS, Dalman RL, Norman PE. Circulating markers of abdominal aortic aneurysm presence and progression. Circulation 2008; 118:2382-2392. This recent review summarizes currently identified circulating markers associated with AAA presence.
11. Golledge J, Karan M, Moran CS, et al. Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions. Eur Heart J 2008; 29:665-672. This study suggests a potential mechanism underlying the relative protection from AAA presence and progression in diabetics.
12. Lenk GM, Tromp G, Weinsheimer S, et al. Whole genome expression profiling reveals a significant role for immune function in human abdominal aortic aneurysms. BMC Genomics 2007; 8:237.
13. Urbonavicius S, Lindholt JS, Vorum H, et al. Proteomic identification of differentially expressed proteins in aortic wall of patients with ruptured and nonruptured abdominal aortic aneurysms. J Vasc Surg 2009; 49:455-463. This study carries out a proteomic assessment of proteins extracted from biopsies of ruptured and intact AAA. They identified relative up-regulation of peroxiredoxin-2 and down-regulation of vitronectin.
14. Helgadottir A, Thorleifsson G, Magnusson KP, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet 2008; 40:217-224. This is the largest study of a genetic site associated with AAA with replication in multiple cohorts suggesting the association of a site on chromosome 9 with AAA.
15. Thompson AR, Golledge J, Cooper AJ, et al. Sequence variant on 9p21 is associated with the presence of abdominal aortic aneurysm disease but does not have a impact on aneurysmal expansion. Eur J Hum Gen 2009; 17:391-394.
16. Kuivaniemi H, Platsoucas CD, Tilson MD 3rd. Aortic aneurysms: an immune disease with a strong genetic component. Circulation 2008; 117:242-252.
17. Thompson AR, Drenos F, Hafez H, Humphries SE. Candidate gene association studies in abdominal aortic aneurysm disease: a review and metaanalysis. Eur J Vasc Endovasc Surg 2008; 35:19-30. This summary analysis reports an association of genetic polymorphisms in a number of genes including angiotensin-converting enzyme and methyl tetrahydrofolate reductase with AAA.
18. Aneurysm Consortium. Genome wide association studies: identifying the genes that determine the risk of abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2008; 36:395-396. This editorial outlines a current Welcome Trust funded genome wide association study for AAA.
19. Sakalihasan N, Van Damme H, Gomez P, et al. Positron emission tomography (PET) evaluation of abdominal aortic aneurysm (AAA). Eur J Vasc Endovasc Surg 2002; 23:431-436.
20. Sakalihasan N, Hustinx R, Limet R. Contribution of PET scanning to the evaluation of abdominal aortic aneurysm. Semin Vasc Surg 2004; 17:144-153.
21. Reeps C, Essler M, Pelisek J, et al. Increased 18F-fluorodeoxyglucose uptake in abdominal aortic aneurysms in positron emission/computed tomography is associated with inflammation, aortic wall instability, and acute symptoms. J Vasc Surg 2008; 48:417-423. This study reports the first correlation between FDG uptake and histological changes within human AAA.
22. Truijers M, Kurvers HA, Bredie SJ, et al. In vivo imaging of abdominal aortic aneurysms: increased FDG uptake suggests inflammation in the aneurysm wall. J Endovasc Ther 2008; 15:462-467.
23. Sarda-Mantel L, Coutard M, Rouzet F, et al. 99mTc-annexin-V functional imaging of luminal thrombus activity in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2006; 26:2153-2159.
24. Lederle FA, Nelson DB, Joseph AM. Smokers' relative risk for aortic aneurysm compared with other smoking-related diseases: a systematic review. J Vasc Surg 2003; 38:329-334.
25. Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneurysms. Circulation 2008; 117:1883-1889.
26. Mosorin M, Juvonen J, Biancari F, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 2001; 34:606-610.
27. Vammen S, Lindholt JS, Ostergaard L, et al. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg 2001; 88:1066-1072.
28. Hackmann AE, Rubin BG, Sanchez LA, et al. A randomized, placebocontrolled trial of doxycycline after endoluminal aneurysm repair. J Vasc Surg 2008; 48:519-526. This is the first medication trial in combination with endovascular AAA repair.
29. Abisi S, Burnand KG, Humphries J, et al. Effect of statins on proteolytic activity in the wall of abdominal aortic aneurysms. Br J Surg 2008; 95:333-337. This study reports reduced MMP-9, cathepsin H and cathepsin L in aortic biopsies from patients receiving statins.
30. Steinmetz EF, Buckley C, Shames ML, et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg 2005; 241:92-101.
31. Kalyanasundaram A, Elmore JR, Manazer JR, et al. Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg 2006; 43:117-124.
32. Shiraya S, Miyake T, Aoki M, et al. Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration. Atherosclerosis 2009; 202:34-40. This is the latest of a series of publications suggesting statins reduce AAA formation in rodent models.
33. Sukhija R, Aronow WS, Sandhu R, et al. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 2006; 97:279-280.
34. Schouten O, van Laanen JH, Boersma E, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 2006; 32:21-26.
35. Schlösser FJ, TangelderMJ, Verhagen HJ, et al., SMART study group. Growth predictors and prognosis of small abdominal aortic aneurysms. J Vasc Surg 2008; 47:1127-1133. This study is one of three cohort investigations reporting an association between statin prescription and reduced small AAA progression.
36. Lu H, Rateri DL, Cassis LA, Daugherty A. The role of the renin-angiotensin system in aortic aneurysmal diseases. Curr Hypertens Rep 2008; 10:99-106.
37. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105:1605-1612.
38. Nishimoto M, Takai S, Fukumoto H, et al. Increased local angiotensin II formation in aneurysmal aorta. Life Sci 2002; 71:2195-2205.
39. Tsunemi K, Takai S, Nishimoto M, et al. Possible roles of angiotensin II-forming enzymes, angiotensin converting enzyme and chymase-like enzyme, in the human aneurysmal aorta. Hypertens Res 2002; 25:817-822.
40. Jones GT, Thompson AR, van Bockxmeer FM, et al. Angiotensin II type 1 receptor 1166C polymorphism is associated with abdominal aortic aneurysm in three independent cohorts. Arterioscler Thromb Vasc Biol 2008; 28:764-770. This study is the first to show association between a genetic polymorphism in angiotensin II type 1 receptor and AAA in three distinct populations.
41. Nagashima H, Uto K, Sakomura Y, et al. An angiotensin-converting enzyme inhibitor, not an angiotensin II type-1 receptor blocker, prevents beta-aminopropionitrile monofumarate-induced aortic dissection in rats. J Vasc Surg 2002; 36:818-823.
42. Liao S, Miralles M, Kelley BJ, et al. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg 2001; 33:1057-1064.
43. Kaschina E, Schrader F, Sommerfeld M, et al. Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation. J Hypertens 2008; 26:2361-2373. This study demonstrated that telmisartan inhibits elastase-induced AAA formation in rats.
44. Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet 2006; 368:659-665.
45. Ahimastos AA, Aggarwal A, D'Orsa KM, et al. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. J Am Med Assoc 2007; 298:1539-1547.
46. Brooke BS, Habashi JP, Judge DP, et al. Angiotensin II blockade and aorticroot dilation in Marfan's syndrome. N Engl J Med 2008; 358:2787-2795.
47. Triggiani M, Patella V, Staiano RI, et al. Allergy and the cardiovascular system. Clin Exp Immunol 2008; 153 (Suppl 1):7-11.
48. Sun J, Sukhova GK, Yang M, et al. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest 2007; 117:3359-3368.
49. Tsuruda T, Kato J, Hatakeyama K, et al. Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res 2008; 102:1368-1377. These two studies suggest that mast cells are involved in AAA formation in rodent models and that mast cell stabilization protects from AAA development.
50. Fang KC, Raymond WW, Blount JL, Caughey GH. Dog mast cell alphachymase activates progelatinase B by cleaving the Phe88-Gln89 and Phe91-Glu92 bonds of the catalytic domain. J Biol Chem 1997; 272:25628-25635.
51. Furubayashi K, Takai S, Jin D, et al. Chymase activates promatrix metalloproteinase-9 in human abdominal aortic aneurysm. Clin Chim Acta 2008; 388:214-216.
52. Inoue N, Muramatsu M, Jin D, et al. Effects of chymase inhibitor on angiotensin II-induced abdominal aortic aneurysm development in apolipoprotein E-deficient mice. Atherosclerosis 2009; 359-364. This study reports that chymase inhibition reduces AAA development in a rodent model of AAA.
53. Furubayashi K, Takai S, Jin D, et al. The significance of chymase in the progression of abdominal aortic aneurysms in dogs. Hypertens Res 2007; 30:349-357.
54. Shimizu T, Kanai K, Kyo Y, et al. Effect of tranilast on matrix metalloproteinase production from neutrophils in-vitro. J Pharm Pharmacol 2006; 58:91-99.
55. Eliason JL, Hannawa KK, Ailawadi G, et al. Neutrophil depletion inhibits experimental abdominal aortic aneurysm formation. Circulation 2005; 112: 232-240.
56. Pae HO, Jeong SO, Koo BS, et al. Tranilast, an orally active antiallergic drug, up-regulates the anti-inflammatory heme oxygenase-1 expression but downregulates the pro-inflammatory cyclooxygenase-2 and inducible nitric oxide synthase expression in RAW264.7 macrophages. Biochem Biophys Res Commun 2008; 371:361-365.
57. Kagitani S, Ueno H, Hirade S, et al. Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats. J Hypertens 2004; 22:1007-1015.
58. Ward MR, Sasahara T, Agrotis A, et al. Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries. Atherosclerosis 1998; 137:267-275.
59. Miyazawa K, Fukuyama J, Misawa K, et al. Tranilast antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells. Atherosclerosis 1996; 121:167-173. (Pubitemid 26125973)
60. Saiura A, Sata M, Hirata Y, et al. Tranilast inhibits transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation. Eur J Pharmacol 2001; 433:163-168.
61. Matsumura T, Kugiyama K, Sugiyama S, et al. Suppression of atherosclerotic development in Watanabe heritable hyperlipidemic rabbits treated with an oral antiallergic drug, tranilast. Circulation 1999; 99:919-924.
62. Doggrell SA, Wanstall JC. Vascular chymase: pathophysiological role and therapeutic potential of inhibition. Cardiovasc Res 2004; 61:653-662.
63. Holmes DR Jr, Savage M, LaBlanche JM, et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2002; 106:1243-1245.
64. Wang Y, Shiota N, Leskinen MJ, et al. Mast cell chymase inhibits smooth muscle cell growth and collagen expression in vitro: transforming growth factor-beta1-dependent and-independent effects. Arterioscler Thromb Vasc Biol 2001; 21:1928-1933.
65. Golledge J, Eagle KA. Acute aortic dissection. Lancet 2008; 372:55-66.
66. Leskinen MJ, Lindstedt KA, Wang Y, Kovanen PT. Mast cell chymase induces smooth muscle cell apoptosis by a mechanism involving fibronectin degradation and disruption of focal adhesions. Arterioscler Thromb Vasc Biol 2003; 23:238-243.
67. Golledge J, Wolanski P, Parr A, Buttner P. Measurement and determinants of infrarenal aortic thrombus volume. Eur Radiol 2008; 18:1987-1994.
68. Houard X, Rouzet F, Touat Z, et al. Topology of the fibrinolytic system within the mural thrombus of human abdominal aortic aneurysms. J Pathol 2007; 212:20-28.
69. Hans SS, Jareunpoon O, Balasubramaniam M, Zelenock GB. Size and location of thrombus in intact and ruptured abdominal aortic aneurysms. J Vasc Surg 2005; 41:584-588.
70. Bluestein D, Dumont K, De Beule M, et al. Intraluminal thrombus and risk of rupture in patient specific abdominal aortic aneurysm: FSI modelling. Comput Methods Biomech Biomed Engin 2009; 12:73-81.
71. Gasser TC, GörgïlïG, Folkesson M, Swedenborg J. Failure properties of intraluminal thrombus in abdominal aortic aneurysm under static and pulsating mechanical loads. J Vasc Surg 2008; 48:179-188.
72. Dai J, Louedec L, Philippe M, et al. Effect of blocking platelet activation with AZD6140 on development of abdominal aortic aneurysm in a rat aneurismal model. J Vasc Surg 2009; 49:719-727. This study reports that a competitive antagonist of ADP platelet activation reduced AAA development at 42 days in a rat transplant model. This effect was associated with a reduction in intraluminal thrombus, platelets, neutrophils and MMP-9 staining.
73. Touat Z, Ollivier V, Dai J, et al. Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution. Am J Pathol 2006; 168:1022-1030.
74. Lindholt JS, Sorensen HT, Michel JB, et al. Low-dose aspirin may prevent growth and later surgical repair of medium-sized abdominal aortic aneurysms. Vasc Endovascular Surg 2008; 42:329-334. This study reported the association of aspirin prescription with reduced small AAA progression.
75. Chun HJ, Ali ZA, Kojima Y, et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 2008; 118:3343-3354.
76. Qian HS,GuJM, Liu P, et al. Overexpression of PAI-1 prevents the development of abdominal aortic aneurysm in mice. Gene Ther 2008; 15:224-232.
77. Yoshimura K, Aoki H, Ikeda Y, et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 2005; 11:1330-1338.
78. Golledge J, Clancy P, Jamrozik K, Norman PE. Obesity, adipokines, and abdominal aortic aneurysm: Health inMen study. Circulation 2007; 116:2275-2279.